In a challenge study the efficacy of ECONOR was tested in two dose levels (1.45 and 2.55mg/kg bw - 25/50ppm ; treatment period: 21 days post challenge). 
 

Results: ECONOR was highly effective in controlling Ileitis. Significant reduction of diarrhoea, anorexia and lesion score with more pronounced efficacy at 2.55mg/kg body weight.
 

 
 

Average daily gain (kg/hd/day)
 

 

Means with the same letter are not different ab = p< 0.05   (Winkelman et al. 2000)

 
 

Diarrhoea score
 

 

Means with the same letter are not different abc = p< 0.05 / AB = p<0.01   (Winkelman et al. 2000)

 
 

Anorexia score
 

 

Means with the same letter are not different ab = p< 0.05 AB = p<0.01   (Winkelman et al. 2000)

 
 

Lesion Score
 

 

Means with the same letter are not different ab = p< 0.05   (Winkelman et al. 2000)

In an artificial infection study the efficacy of ECONOR was tested in different dose levels (25, 37.5, 50; treatment period: 5 days prior + 21 days post challenge) in comparison to Tylosin (110ppm). 
 
Results: Substantial reduction of the clinical signs after severe challenge. Dose response and significant improvement of weight gain at 50ppm in comparison to Tylosin group. 
 

 
 

Average daily gain (kg/hd/day)
 

Dosage (ppm)

abc Means with the same letter are not different (ab = p< 0.05)   (Winkelman et al. 2000)

 
 

Individual diarrhoea score day 14, score 1-4, 1=normal 4=severe)
 

Dosage (ppm)

ab Means with the same letter are not different (p< 0.01)   (Winkelman et al. 2000)

 
 

Mortality (in %)
 

Dosage (ppm)

ab Means with the same letter are not different (p< 0.001)   (Winkelman et al. 2000)